Chiasma, Inc. Banner Image

Chiasma, Inc.

  • Ticker CHMA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Chiasma, Inc. Logo Image
  • 51-200 Employees
  • Based in Needham, Massachusetts
Chiasma is focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPEĀ®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. On June 26, 2020, ChiasmaMore received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog approved by the FDA. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.
4.8 / 5.0 (148)

Chiasma, Inc. reports have an aggregate usefulness score of 4.8 based on 148 reviews.

Chiasma, Inc.

Most Recent Annual Report

Chiasma, Inc.
MOST RECENT 2020 Annual Report and Form 10K

Older/Archived Annual Reports

Chiasma, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!